Health Economics›CNS lymphoma›Upfront therapy non-randomized or retrospective data

Upfront therapy non-randomized or retrospective data

CNS lymphoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
R-MP Variant #01 Partial	—	R 181 942	42d	—	—	~3	~R 260 873 indirect	—
R-MCP (CCNU) Variant #01 Partial	—	R 104 227	43d	—	—	~3	~R 312 682 indirect	—
MATRix-RICE Variant #01 Partial	—	R 71 017	21d	—	—	~3	~R 213 051 indirect	—
Nordic Regimen, younger patients Variant #01 Partial	—	R 39 068	21d	—	—	~4	~R 53 331 indirect	—
Nordic Regimen, older patients Variant #01 Partial	—	R 37 550	21d	—	—	~4	~R 42 739 indirect	—
MT-R Variant #01	—	R 28 560	14d	—	—	~5	~R 31 824 indirect	—
R-MPV Variant #01 Partial	—	R 26 434	14d	—	—	~7	~R 185 039 indirect	—
Methotrexate and Rituximab Variant #01	—	R 26 108	14d	—	—	~6	~R 156 645 indirect	—
Methotrexate-Cytarabine and Thiotepa Variant #01 Partial	—	R 5 070	28d	—	—	~4	~R 20 281 indirect	—
Methotrexate-Cytarabine Variant #01	—	R 4 867	30d	—	—	~5	~R 10 343 indirect	—
Lomustine, Methotrexate, Procarbazine, Methylprednisolone Variant #01 Partial	—	R 3 225	45d	—	—	~1	~R 3 225 indirect	—
MVBP Variant #01 Partial	—	R 1 212	—	—	—	~2	~R 2 425 indirect	—
Lomustine, Methotrexate, Procarbazine Variant #01 Partial	—	R 609	45d	—	—	~3	~R 1 826 indirect	—
MPV Variant #01 Partial	—	R 529	14d	—	—	~5	~R 2 647 indirect	—

14 of 14 regimens shown